New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies

Expert Review of Anticancer Therapy

Volumn 12, Issue 4, 2012, Pages 457-467

  Grande, Enrique ^a   Earl, Julie ^b   Fuentes, Raquel ^a   Carrato, Alfredo ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

E3 ubiquitinin ligase inhibitors; gastrointestinal cancer; MLN4924; NAE inhibitors; NEDD8 activating enzyme; ubiquitin proteasome system inhibitors; UPS

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; DELANZOMIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MLN 4924; MLN 9708; NEDD8 PROTEIN; ONX 0912; OXALIPLATIN; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SERDEMETAN; SORAFENIB; SUMO PROTEIN; THREONINE PROTEINASE INHIBITOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; UBIQUITINATION; VOMITING;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84859787749     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.26     Document Type: Review

References (110)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat. Rev. Cancer 6(10), 776-788 (2006). (Pubitemid 44450466)
3. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discov. 10(1), 29-46 (2011).
4. Crusio KM, King B, Reavie LB, Aifantis I. The ubiquitous nature of cancer: The role of the SCF(Fbw7) complex in development and transformation. Oncogene 29(35), 4865-4873 (2010).
5. Shabek N, Ciechanover A. Degradation of ubiquitin: The fate of the cellular reaper. Cell Cycle 9(3), 523-530 (2010).
6. Chen D, Frezza M, Schmitt S, Kanwar J, Dou PQ. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr. Cancer Drug Targets 11(3), 239-253 (2011).
7. Milano A, Perri F, Caponigro F. The ubiquitin-proteasome system as a molecular target in solid tumors: An update on bortezomib. Onco. Targets Ther. 2, 171-178 (2009).
8. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78, 477-513 (2009).
9. Deveraux Q, Ustrell V, Pickart C, Rechsteiner M. A 26 S protease subunit that binds ubiquitin conjugates. J. Biol. Chem. 269(10), 7059-7061 (1994). (Pubitemid 24217884)
10. Schreiner P, Chen X, K. Husnjak et al. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature 453(7194), 548-552 (2008). (Pubitemid 351733316)
11. Groll M, Ditzel L, Lowe J et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386(6624), 463-471 (1997). (Pubitemid 27164066)
12. Wilk, S, Orlowski M. Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. 40(3), 842-849 (1983). (Pubitemid 13146816)
13. Bennett EJ, Harper JW. DNA damage: Ubiquitin marks the spot. Nat. Struct. Mol. Biol. 15(1), 20-22 (2008).
14. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22, 159-180 (2006).
15. Singhal S, Taylor MC, Baker RT. Deubiquitylating enzymes and disease. BMC Biochem. 9(Suppl.1), S3 (2008).
16. Geiss-Friedlander, R, Melchior F. Concepts in sumoylation: A decade on. Nat. Rev. Mol. Cell Biol. 8(12), 947-956 (2007). (Pubitemid 350176509)
17. Nijman SM, Luna-Vargas, Velds A et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123(5), 773-786 (2005). (Pubitemid 41721026)
18. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-Activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 15(12), 3912-3916 (2009).
19. Andersen JB, Hassel BA. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe? Cytokine Growth Factor Rev. 17(6), 411-421 (2006). (Pubitemid 44793124)
20. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1(7), 708-716 (2010).
21. Xie Z, Klionsky DJ. Autophagosome formation: Core machinery and adaptations. Nat. Cell. Biol. 9(10), 1102-1109 (2007). (Pubitemid 47500484)
22. Tatham MH, Kim S, Jaffray E et al. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat. Struct. Mol. Biol. 12(1), 67-74 (2005). (Pubitemid 40082919)
23. Moschos SJ, Jukic DM, Athanassiou C et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum. Pathol. 41(9), 1286-1298 (2010).
24. Alarcon-Vargas D, Ronai Z. SUMO in cancer - Wrestlers wanted. Cancer Biol. Ther. 1(3), 237-242 (2002).
25. Foulkes WD. p53 - Master and commander. N. Engl. J. Med. 357(25), 2539-2541 (2007). (Pubitemid 350294220)
26. Geng, J, Klionsky DJ. The Atg8 and Atg12 ubiquitin-like conjugation systems in macroautophagy. Protein modifications: Beyond the usual suspects' review series. EMBO Rep. 9(9), 859-864 (2008).
27. Desai SD, Wood LM, Tsai YC et al. ISG15 as a novel tumor biomarker for drug sensitivity. Mol. Cancer Ther. 7(6), 1430-1439 (2008).
28. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 458(7237), 438-444 (2009).
29. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol. Rev. 82(2), 373-428 (2002). (Pubitemid 34654457)
30. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell Biol. 6(4), 287-297 (2005).
31. Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene 23(11), 2096-2106 (2004). (Pubitemid 38496739)
32. Toledo, F, Wahl GM, Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6(12), 909-923 (2006). (Pubitemid 44862676)
33. Bischof O, Schwamborn K, Martin N et al. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 22(6), 783-794 (2006).
34. Brooks CL, Li M, Hu M, Shi Y, Gu W. The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 26(51), 7262-7266 (2007). (Pubitemid 350085320)
35. Kon N, Kobayashi Y, Li M et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29(9), 1270-1279 (2010).
36. Laurie NA, Donovan SL, Shih CS et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115), 61-66 (2006). (Pubitemid 44684754)
37. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13(6), 879-886 (2004). (Pubitemid 38438482)
38. Lind H, Ekstrom PO, Ryberg D et al. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non-small-cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 16(10), 2077-2081 (2007). (Pubitemid 47621183)
39. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer 119(3), 718-721 (2006). (Pubitemid 43955729)
40. Masuya D, Huang C, Liu D et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J. Pathol. 208(5), 724-732 (2006).
41. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011).
42. Ivan M, Kondo K, Yang H et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292(5516), 464-468 (2001). (Pubitemid 32335941)
43. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100(1), 24-28 (2009).
44. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: Insights from genetic studies in mice. Cell Death Differ. 15(4), 650-659 (2008). (Pubitemid 351405068)
45. Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol. Biomarkers Prev. 20(7), 1296-1302 (2011).
46. Van Cutsem E, Dicato M, Arber N et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: Expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann. Oncol. 21(Suppl. 6), vi1-vi10 (2010).
47. Lui TT, Lacroix C, Ahmed SM et al. The ubiquitin-specific protease USP34 regulates axin stability and Wnt/beta-catenin signaling. Mol. Cell Biol. 31(10), 2053-2065 (2011).
48. Voutsadakis IA. The ubiquitin-proteasome system in colorectal cancer. Biochim. Biophys. Acta 1782(12), 800-808 (2008).
49. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 66(18), 9245-9251 (2006). (Pubitemid 44521146)
50. Ding WX, Ni HM, Chen X et al. A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol. Cancer Ther. 6(3), 1062-1069 (2007). (Pubitemid 46554577)
51. Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: The roles of the ubiquitin-proteasome system and Cox-2. J. Cell. Mol. Med. 11(2), 252-285 (2007). (Pubitemid 46695694)
52. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 97(9), 4820-4825 (2000). (Pubitemid 30238641)
53. Wu WK, Volta V, Cho CH et al. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem. Biophys. Res. Commun. 386(4), 598-601 (2009).
54. Wu WK, Wu YC, Yu L et al. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells. Biochem. Biophys. Res. Commun. 374(2), 258-263 (2008).
55. Catalano V, Labianca R, Beretta GD et al. Gastric cancer. Crit. Rev. Oncol. Hematol. 71(2), 127-164 (2009).
56. Nakata W, Hayakawa Y, Nakagawa H et al. Anti-Tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Int. J. Oncol. 39(6), 1529-1536 (2011).
57. Hatakeyama S. TRIM proteins and cancer. Nat. Rev. Cancer 11(11), 792-804 (2011).
58. Sugiura T, Miyamoto K. Characterization of TRIM31, upregulated in gastric adenocarcinoma, as a novel RBCC protein. J. Cell. Biochem. 105(4), 1081-1091 (2008).
59. Sugiura T. The cellular level of TRIM31, an RBCC protein overexpressed in gastric cancer, is regulated by multiple mechanisms including the ubiquitin-proteasome system. Cell Biol. Int. 35(7), 657-661 (2011).
60. Bossola M, Muscaritoli M, Costelli P et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. 237(3), 384-389 (2003). (Pubitemid 38176454)
61. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 378(9791), 607-620 (2011).
62. Ni XG, Zhou L, Wang GQ et al. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol. Med. 14(9-10), 582-589 (2008).
63. Sloss CM, Wang F, Liu R et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14(16), 5116-5123 (2008).
64. Okuda K. Hepatocellular carcinoma. J. Hepatol. 32(1 Suppl.), 225-237 (2000). (Pubitemid 30123637)
65. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology, 140(5), 1410-1426 (2011).
66. Dawson SP. Hepatocellular carcinoma and the ubiquitin-proteasome system. Biochim. Biophys. Acta 1782(12), 775-784 (2008).
67. Krzywda S, Brzozowski AM, Higashitsuji H et al. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J. Biol. Chem. 279(2), 1541-1545 (2004). (Pubitemid 38082684)
68. Lim IK. Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fisher 344 male rats [Mechanisms of Ageing and Development 123 (2002) 1665-1680]. Mech. Ageing Dev. 124(5), 697-708 (2003). (Pubitemid 36555919)
69. Dawson S, Apcher S, Mee M et al. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J. Biol. Chem. 277(13), 10893-10902 (2002). (Pubitemid 34952844)
70. Aufiero, B, Schneider RJ. The hepatitis B virus X-gene product trans-Activates both RNA polymerase II and III promoters. EMBO J. 9(2), 497-504 (1990).
71. Dandri, M., Schirmacher P, Rogler CE. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J. Virol. 70(8), 5246-5254 (1996). (Pubitemid 26240697)
72. Kalra N, Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett. 580(2), 431-436 (2006). (Pubitemid 43089667)
73. Marin I, Lucas JI, Gradilla AC, Ferrus A. Parkin and relatives: The RBR family of ubiquitin ligases. Physiol. Genomics 17(3), 253-263 (2004). (Pubitemid 38924170)
74. Wang F, Denison S, Lai JP et al. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40(2), 85-96 (2004). (Pubitemid 38579877)
75. Lee C.G, Ren J, Cheong IS et al. Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 22(17), 2592-2603 (2003). (Pubitemid 36605607)
76. Luedde T, Schwabe RF. NF-kappaB in the liver - Linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8(2), 108-118 (2011).
77. Bavi P, Uddin S, Ahmed M et al. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am. J. Pathol. 178(5), 2109-2120 (2011).
78. Uddin S, Siraj AK, Al-Rasheed M et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab. 93(10), 4088-4097 (2008).
79. Mackay H, Hedley D, Major P et al. A Phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 11(15), 5526-5533 (2005). (Pubitemid 41060829)
80. Caponigro F, Lacombe D, Twelves C et al. An EORTC Phase I study of bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur. J. Cancer 45(1), 48-55 (2009).
81. Kozuch PS, Rocha-Lima CM, Dragovich T et al. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized Phase II study. J. Clin. Oncol. 26(14), 2320-2326 (2008).
82. Shah MA, Power DG, Kindler HL et al. A multicenter, Phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest. New Drugs 29(6), 1475-1481 (2011).
83. Jatoi A, Dakhil SR, Foster NR et al. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: Phase II results from the North Central Cancer Treatment Group (N044B). J. Thorac. Oncol. 3(5), 516-520 (2008). (Pubitemid 351630280)
84. Alberts SR, Foster NR, Morton RF et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. 16(10), 1654-1661 (2005). (Pubitemid 41510140)
85. Kim GP, Mahoney MR, Szydlo D et al. An international, multicenter Phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest. New Drugs 30(1), 387-394 (2012).
86. Aad G, Abbott B, Abdallah J et al. Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys. Rev. Lett. 105(25), 252303 (2010).
87. Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-Type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther. 9(9), 2545-2557 (2010).
88. Tabernero J, Dirix L, Schoffski P et al. A Phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin. Cancer Res. 17(19), 6313-6321 (2011).
89. Yamada T, Christov K, Das Gupta K T, Beattie CW. Mechanism of action of p28, a first-in-class, non-HDM2 mediated peptide inhibitor of p53 ubiquitination, in 2011 ASCO Annual Meeting 2011. J. Clin. Oncol. 29(Suppl.), Abstract e13513 (2011).
90. Richards JM., Warso MA, Mehta D et al. A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. 2011 ASCO Annual Meeting 2011. J. Clin. Oncol. 29(Suppl.), Abstract 2511 (2011).
91. Yang Y, Ludwig RL, Jensen JP et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7(6), 547-559 (2005). (Pubitemid 40799248)
92. Milhollen MA, Narayanan U, Soucy TA et al. Inhibition of NEDD8-Activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 71(8), 3042-3051 (2011).
93. Kauh JS, Shapiro G, Cohen RB et al. MLN4924, an investigational NEDD8-Activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules, in 2011 ASCO Annual Meeting 2011. J. Clin. Oncol. 29(Suppl.), Abstract 3013 (2011).
94. Wei D, Li H, Yu J et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-Activating enzyme inhibitor. Cancer Res. 72(1), 282-293 (2012).
95. Mitsui T., Hirayama K, Aoki S et al. Identification of a novel chemical potentiator and inhibitors of UCH-L1 by in silico drug screening. Neurochem. Int. 56(5), 679-686 (2010).
96. D'Arcy P, Brnjic S, Olofsson MH et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat. Med. 17(12), 1636-1640 (2011).
97. Khan, M.L, Stewart AK. Carfilzomib: A novel second-generation proteasome inhibitor. Future Oncol. 7(5), 607-612 (2011).
98. O'Connor OA, Stewart AK, Vallone M et al. A Phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 15(22), 7085-7091 (2009).
99. Fenical W, Jensen PR, Palladino MA et al. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 17(6), 2175-2180 (2009).
100. Obaidat A, Weiss J, Wahlgren B et al. Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs. J. Pharmacol. Exp. Ther. 337(2), 479-486 (2011).
101. Hamlin PA, Aghajanian C, Younes A et al. First-in-human Phase I study of the novel structure proteasome inhibitor NPI-0052, in 2009 ASCO Annual Meeting 2009. J. Clin. Oncol. 27(Suppl.) 15s (2009).
102. Chauhan D, Singh AV, Aujay M et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116(23), 4906-4915 (2010).
103. Papadopoulos KP, Mendelson DS, Tolcher AW et al. A Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors, in 2011 ASCO Annual Meeting 2011. J. Clin. Oncol. 29(Suppl.), Abstract 3075 (2009).
104. Piva R, Ruggeri B, Williams M et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5), 2765-2775 (2008).
105. Kupperman E, Lee EC, Cao Y et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70(5), 1970-1980 (2010).
106. Rodler M, Vadon V, Pekar K. [Remarks on the work 'Study of H2S synthesis capability of various bacteria' by Rodler M, V. Vadon and K. Pekar in the Zbl Bakt (Orig) 206, 117-122 (1968)]. Zentralbl. Bakteriol. Orig. 209(1), 71-73 (1968).
107. Kuhn D, Orlowski. RCB. Second generation proteasome inhibitors: Carfilzomib and immunoproteasome-specific inhibitors (IPSIs). Curr. Cancer Drug Targets 11(3), 285-295 (2011).
108. Ronconi L, Aldinucci D, Dou QP, Fregona D. Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes. Anticancer Agents Med. Chem. 10(4), 283-292 (2010).
109. Casini A, Messori L. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr. Top. Med. Chem. 11(21), 2647-2660 (2011).
110. Zhang X, Frezza M, Milacic V et al. Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J. Cell. Biochem. 109(1), 162-172 (2010)